Ironwood Pharmaceuticals, Inc. IRWD
3.73 USD +0.23 (+6.43%)
Nov 4, 2026, 1:04 PM EST
3.58 Day range 3.73
1.87 52-week range 5.39
- YTD
- +10.53%
- 1 year
- +99.20%
Analyst view
Consensus: buy
Buy
Price target (mean) 12.50 +235.6% upside
Now 3.73
- Target (low)
- 5.00
- Target (mean)
- 12.50
- Target (high)
- 23.00
Ratings (0m) 6 5 buy · 1 hold · 0 sell
- Strong buy2
- Buy3
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 6
- 1 month ago 6
- 2 months ago 7
- 3 months ago 7
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.15667 | 0.05 – 0.35 | 0.00 | 0.0% | 92.50M | -21.3% | 3 |
| Next quarter | 0.04 | 0.03 – 0.05 | -0.02 | +300.0% | 81.90M | +9.4% | 2 |
| Current year | 0.21667 | 0.07 – 0.50 | -6.27 | +103.5% | 353.42M | -20.2% | 3 |
| Next year | 0.2425 | 0.13 – 0.39 | 0.21667 | +11.9% | 348.40M | -1.4% | 4 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 9, 2024 | Leerink Partners | Initiated | — | Market Perform |
| Aug 9, 2024 | Wells Fargo | Maintained | Overweight | Overweight |
| Aug 9, 2024 | Craig-Hallum | Maintained | Buy | Buy |
| May 10, 2024 | Craig-Hallum | Maintained | Buy | Buy |
| Mar 1, 2024 | Wells Fargo | Maintained | Overweight | Overweight |
| Feb 16, 2024 | Piper Sandler | Maintained | Overweight | Overweight |
| Jan 17, 2024 | Craig-Hallum | Initiated | — | Buy |
| Dec 14, 2023 | Wells Fargo | Initiated | — | Overweight |
| Sep 28, 2023 | JMP Securities | Initiated | — | Market Outperform |
| May 23, 2023 | Piper Sandler | Maintained | Overweight | Overweight |
| Aug 16, 2022 | Wells Fargo | Maintained | — | Equal-Weight |
| Apr 22, 2022 | Piper Sandler | Initiated | — | Overweight |
| Oct 12, 2021 | Morgan Stanley | Maintained | — | Equal-Weight |
| Jul 16, 2021 | Morgan Stanley | Maintained | — | Equal-Weight |
| Feb 22, 2021 | Morgan Stanley | Maintained | — | Equal-Weight |
| Feb 19, 2021 | Morgan Stanley | Maintained | — | Equal-Weight |
| Nov 6, 2020 | Credit Suisse | Maintained | — | Neutral |
| Nov 6, 2020 | Morgan Stanley | Maintained | — | Equal-Weight |
| Sep 30, 2020 | Wells Fargo | Downgrade | Overweight | Equal-Weight |
| Aug 7, 2020 | Morgan Stanley | Maintained | — | Equal-Weight |
| Jul 15, 2020 | Morgan Stanley | Maintained | — | Equal-Weight |
| Jun 1, 2020 | Credit Suisse | Maintained | — | Neutral |
| May 11, 2020 | HC Wainwright & Co. | Reiterated | — | Neutral |
| May 7, 2020 | Morgan Stanley | Maintained | — | Equal-Weight |
| Apr 30, 2020 | Wells Fargo | Maintained | — | Overweight |
| Apr 15, 2020 | Morgan Stanley | Maintained | — | Equal-Weight |
| Mar 27, 2019 | Morgan Stanley | Upgrade | Underweight | Equal-Weight |
| Feb 25, 2019 | HC Wainwright & Co. | Upgrade | Sell | Neutral |
| Jan 24, 2019 | JP Morgan | Upgrade | Underweight | Neutral |
| Nov 7, 2018 | JP Morgan | Downgrade | Neutral | Underweight |